The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).
 
Jonathan Strosberg
Consulting or Advisory Role - Boehringer Ingelheim; Exelixis
Research Funding - Alphamedix (Inst); ITM Solucin (Inst); Novartis (Inst); RayzeBio (Inst)
 
Tyler Zemla
No Relationships to Disclose
 
Susan Geyer
No Relationships to Disclose
 
Michael Knopp
No Relationships to Disclose
 
Spencer Behr
Honoraria - University of Texas Medical Branch at Galvaston
Consulting or Advisory Role - Advanced Accelerator Applications; GenVivo; More Health; Progenics
Research Funding - Cancer Targeted Technology
 
Sydney Pulsipher
No Relationships to Disclose
 
Jared Acoba
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Colon Cancer Alliance; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; Guardant Health; KLJ Associates; Merus; Pfizer; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Takeda
 
Edward Wolin
Consulting or Advisory Role - Exelixis
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Bhavana Konda
Research Funding - Eisai (Inst); Lilly (Inst); Merck (Inst); Xencor (Inst)
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
Bernard Tawfik
Other Relationship - Ipsen
 
Nitya Raj
Consulting or Advisory Role - Crinetics Pharmaceuticals
Speakers' Bureau - ITM Oncologics
Research Funding - Camarus AB (Inst); Corcept Therapeutics (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Camurus
 
Shagufta Shaheen
Consulting or Advisory Role - Crinetics Pharmaceuticals; Exelixis
Travel, Accommodations, Expenses - Dava Oncology
 
Namrata Vijayvergia
Honoraria - Guidepoint Global
Consulting or Advisory Role - Exelixis; RayzeBio; Taiho Oncology
Research Funding - Bristol-Myers Squibb/Medarex (Inst); ITM Isotope Technologies Munich (Inst); Oryzon Genomics (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Jeffrey Meyerhardt
Employment - Dana-Farber Cancer Institute; Newton Wellesley Hospital (I)
Research Funding - Boston Biomedical (Inst)
 
Jennifer Chan
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Curium Pharma; Ipsen; Lantheus Medical Imaging; Novartis; Pfizer (I)
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from UpToDate for authorship
(OPTIONAL) Uncompensated Relationships - Camurus